Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of its performance and outlook.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into its performance and outlook.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting evolving investor perceptions amid mixed financial metrics and sector comparisons. This article analyses the recent changes in key valuation ratios, their implications for price attractiveness, and how Novelix stacks up against its peers in the retailing sector.

Novelix Pharmaceuticals Ltd has seen its quality grade upgraded from below average to average, reflecting a nuanced shift in its business fundamentals. While the company demonstrates impressive sales growth and a clean debt profile, key profitability metrics such as ROCE and ROE remain subdued, indicating areas of concern for investors seeking consistent returns.

Novelix Pharmaceuticals Ltd has delivered its strongest quarterly financial performance to date in the December 2025 quarter, with record-breaking sales and profit metrics signalling a significant turnaround. Despite a mixed short-term stock return relative to the Sensex, the company’s financial trend has shifted from positive to very positive, reflecting robust operational execution and margin expansion in a challenging retailing sector environment.

Novelix Pharmaceuticals Limited has delivered its strongest quarterly performance in years during Q3 FY26, posting net sales of ₹48.40 crores and net profit of ₹1.00 crores—the highest figures in the company's recent operating history. Despite this impressive turnaround from consecutive quarters of losses, the micro-cap pharmaceutical retailer continues to trade at precarious valuations with a market capitalisation of just ₹108.00 crores and a concerning track record that raises serious questions about sustainability.

Novelix Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 05 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Novelix Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 05 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 30 January 2026, providing investors with the latest perspective on the company’s position.

Novelix Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Novelix Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 5 January 2026, reflecting a combination of deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite recent positive quarterly financial results.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 08 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into its performance and outlook.

Novelix Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a distinct absence of buyers. This marks the third consecutive day of losses, reflecting a sustained period of distress selling that has weighed heavily on investor sentiment.